The global AI-enabled imaging modalities market is anticipated to grow at a CAGR of 35.0% during the forecast period. The FDA's approval of a new AI-powered imaging processing software is expected to have significant implications in the market of AI-enabled imaging modalities. The software's accuracy in analysing medical images could improve diagnostic precision, resulting in earlier detection of abnormalities and potentially better patient outcomes. As the software gains clearance for specific medical applications, its usage could expand to a broader range of diagnoses, driving innovation in the field. Companies that integrate the FDA-approved software into their AI-enabled imaging modalities may gain a competitive edge, attracting investments and fostering further advancements. Additionally, increased recognition of AI-enabled imaging by insurance providers and healthcare programs could enhance reimbursement opportunities for medical facilities using these solutions. There are several approval has been done recently. Some of them written below. For instance,
Browse the full report description of “AI-Enabled Imaging Modalities Market Size, Share & Trends Analysis Report by Product Type (Computed Tomography (CT), Magnetic Resonance Imaging (MRI), X-Ray, Ultrasound, Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), and Others, by End-User (Hospitals, Diagnostic Centers, and Research Institutions), and by Application (Cardiology, Oncology, Neurology, Orthopedics, and Gastroenterology) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/ai-enabled-imaging-modalities-market
• In May 2023, Precision DL is an AI-enabled image processing software designed for PET/CT scans that has received FDA clearance. It offers significant improvements in contrast-to-noise ratio, the accuracy of feature quantification, and the diagnosis of small lesions. The software provides an average 42 percent increase in the detection of small, low-contrast lesions, an average 23 percent improvement in CNR, and a 14 percent improvement in the accuracy of feature quantification.
• In May 2023, DiA Imaging Analysis secured FDA clearance for LVivo IQS, a new AI-based vendor-neutral software solution that enables ultrasound users to acquire high-quality interpretable cardiac ultrasound images that can be used to make better clinical assessments of the heart.
• In July 2022, HeartLung Corp.'s ABMD Al- based Software received a final approval from the FDA for its radiology software, with submission number K213760 and primary product code KGI.
Market Coverage
• The market number available for – 2023-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Product Type
o By End-User
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Includes GE HealthCare Technologies Inc., Siemens Healthineers, Philips, Canon Medical Systems Corp., and Hitachi Ltd., among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global AI-Enabled Imaging Modalities Market Report Segment
By Product Type
By End-User
By Application
Global AI-Enabled Imaging Modalities Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ai-enabled-imaging-modalities-market